Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies.
Two patients diagnosed with dementia with Lewy bodies (DLB) presented with prominent behavioral disturbances. The first patient experienced well-formed visual hallucinations, movement disorders, and cognitive decline and was increasingly resistant to care. He was treated with galantamine 4 mg bid, which was increased to 8 mg bid after four weeks. Improvements in behavior, attention, and cognition made it possible for this patient to be transferred back to long-term care after 32 days. The second patient had increasing confusion, fluctuating cognition, agitation, and psychosis. He was given donepezil initially, then switched to galantamine 4 mg bid. He was assessed as stable for discharge with improved behavior control after three weeks. Both patients also were receiving an atypical antipsychotic (quetiapine) and an antidepressant (venlafaxine and sertraline, respectively).
Holm
Alvin C
AC
Geriatric Behavioral Services, Bethesda Rehabilitation Hospital, St. Paul, Minnesota, USA.
D000368:Aged; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D005702:Galantamine / Q000627:therapeutic use*; D006212:Hallucinations / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D020961:Lewy Body Disease / Q000523:psychology*; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000209:etiology*; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology*; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D005702:Galantamine